AbCellera is an antibody discovery and development engine, finding optimal clinical candidates for our partners.
AbCellera is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic – and patients – sooner.With the integrated AbCellera platform, our experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set our partners up for enduring success. We have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 10, 2020 | IPO | $482M | — | — | — | Detail |
May 27, 2020 | Series B | $105M | 8 | DCVC OrbiMed | — | Detail |
May 3, 2020 | Grant | $175.60M | 1 | Government of Canada | — | Detail |
Mar 23, 2020 | Series A | $75M | 5 | DCVC Bio OrbiMed | — | Detail |
Mar 14, 2019 | Grant | $4.80M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
DCVC | Yes | Series B |
OrbiMed | Yes | Series B |
Government of Canada | Yes | Grant |
DCVC Bio | Yes | Series A |
Eli Lilly | — | Series B |
Founders Fund | — | Series B |
Peter Thiel | — | Series B |
Presight Capital | — | Series B |
University of Minnesota | — | Series B |
Viking Global Investors | — | Series B |
AbCellera has acquired 4 organizations. Their most recent acquisition was Lineage Biosciences on Aug 1, 2018. They acquired Lineage Biosciences for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Aug 1, 2018
Lineage Biosciences
|
Biotechnology | acquisition | — | Detail |
Aug 20, 2020
Dualogics - OrthoMab
|
Biotechnology | acquisition | — | Detail |
Nov 18, 2020
Trianni
|
Biotechnology | acquisition | $ 90M | Detail |
Sep 13, 2021
Tetragenetics
|
Biopharma | acquisition | — | Detail |